Ipilimumab In Treating Asian Patient With Advanced Melanoma: The Preliminary Report Of Taiwan Ipilimumab Extended Access Program Group

e20069 Background: Ipilimumab is proved effective in treating patient with advanced melanoma. However, the clinical experiences of ipilimumab have been limited in Asia. In this preliminary report of Taiwan extended access program (EAP) cohort, the efficacy and safety of ipilimumab in Asian patient with advanced melanoma was accessed. Methods: Patients with advanced melanoma which progressed after at least one line of systemic therapy are eligible in our EAP. Patients received ipilimumab 3 mg/kg every 3 weeks for four doses. Patients with stable disease or an objective response to ipilimumab were eligible for retreatment upon disease progression. Tumor assessments were conducted at baseline and week 12. Results: In the Taiwan EAP cohort, 31 were evaluable for response. Of these, 9.6% had an objective immune response, and the immune-related disease control rate was 29.1%. The median duration of follow up were 6.2 (95% CI, 5.3 to 7.5) months. Median progression-free survival was 4.14 (95%CI, 2.8 to 4.5) mont...